Related Experiment Video
Updated: May 5, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
Low plasma Chromium in patients with coronary artery and heart diseases
M Simonoff1, Y Llabador, C Hamon
1Chimie Nucléaire, ERA 144, CENBG, 33170, Bordeaux- Gradignan, France.
Insights
Plasma chromium levels can help predict coronary artery disease (CAD). Lower chromium concentrations indicate a higher likelihood of CAD, potentially reducing the need for invasive cineangiographic examinations.
Area of Science:
- Cardiovascular Medicine
- Clinical Chemistry
- Biomarker Discovery
Background:
- Plasma chromium levels are being investigated as potential biomarkers.
- Coronary artery disease (CAD) diagnosis often relies on invasive procedures.
Purpose of the Study:
- To determine the relationship between plasma chromium concentrations and coronary artery disease.
- To explore the potential of plasma chromium levels to non-invasively predict CAD risk.
Main Methods:
- Plasma chromium concentrations were measured in 150 patients.
- Patients were categorized into three groups: CAD, heart disease (HD) without CAD, and no CAD/HD (N) based on coronary artery cineangiography.
- Weighted average chromium levels were calculated for each group.
Main Results:
- Group N (no CAD/HD) had a significantly higher average plasma chromium level (8.51 ng/mL) compared to Group HD (1.72 ng/mL) and Group CAD (1.05 ng/mL).
- A potential upper limit for plasma chromium was identified at 6 ng/mL, beyond which CAD is unlikely.
Conclusions:
- Plasma chromium levels show a strong inverse correlation with the presence and severity of coronary artery disease.
- Establishing an upper plasma chromium threshold could aid in risk stratification and potentially reduce the need for diagnostic cineangiography.
Abstract:
Plasma chromium concentrations have been determined for 150 patients. These were subjected to coronary artery cineangiography and thereby divided into three groups: group CAD (those with coronary artery disease), group HD (those with heart disease, but no CAD) and group N (those with no CAD and no HD). Weighted, average chromium levels for these groups were 1.05, 1.72, and 8.51 ng/mL, respectively. The distributions of plasma chromium levels for the three groups suggest that an upper limit for plasma chromium may be established (6 ng/mL in this work) beyond which CAD may be considered to be extremely unlikely, thus eliminating the need for a certain number of cineangiographic examinations.
More Related Videos
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease III: Clinical Manifestations

